Refine
Year of publication
- 2013 (63) (remove)
Document Type
- Article (32)
- Doctoral Thesis (24)
- Book (5)
- Conference Proceeding (1)
- Contribution to a Periodical (1)
Has Fulltext
- yes (63)
Is part of the Bibliography
- no (63)
Keywords
- Antibiotic Resistance (1)
- BPTI (1)
- Bioenergetics (1)
- Computation (1)
- Copper decoration (1)
- Cyanobacteria (1)
- Cytochrome Oxidase (1)
- Dimerization (1)
- Drift correction (1)
- Etching (1)
Institute
- Biochemie und Chemie (63) (remove)
ATP synthases are multi-subunit membrane enzymes, which utilize the energy stored in a transmembrane electrochemical ion gradient to produce adenosine-5´-triphosphate (ATP), the universal energy carrier in biological systems. Research on these important enzymes goes back more than 50 years and has produced innumerable studies. The F-type ATP synthase consists of two functionally distinct, but tightly coupled subcomplexes, the water-soluble F1 and the membrane-embedded Fo complex. In its simplest form, F1 consists of five different subunits with a stoichiometry of α 3β3γδε, and harbors three catalytic centers in the α 3β3-headpiece, while Fo consists of three different subunits in a stoichiometry of ab2cn, where n varies between 8 to 15 depending on the species. From a mechanistic standpoint, the complex can also be divided into two different units, namely a stator, α3β3δ-ab2, and a rotor, γε-cn. The enzyme utilizes the energy stored in a transmembrane electrochemical gradient of protons, or in some cases Na+, to drive ATP synthesis. In particular, the downhill translocation of these ions across the Fo complex drives rotation of the γε-cn unit, which is then transduced to the active centers, catalyzing the phosphorylation of adenosine-5`-diphosphate (ADP) with inorganic phosphate (Pi), and the release of ATP....
So far clinical human immunodeficiency virus (HIV) therapy is limited to non-curative treatments. However, as recently shown, alternative approaches such as HIV gene therapy have the potential to functionally cure the disease (e.g. the hematopoietic stem cell (HSC)-transplantation with a CCR5Δ32 homozygous transplant) (1). In contrast to the highly personalized medical treatment applied in the ‘Berlin case’, more broadly applicable approaches are currently under intensive investigation.
One example is the adeno-associated-virus (AAV)-mediated delivery of in vivo secreted antiviral entry inhibitors (iSAVE), the concept of which is based on the direct in vivo administration of a broadly applicable highly potent antiviral gene (here: a C46-derived entry inhibitory peptide interfering with HIV-1 membrane fusion). The AAV-based gene delivery is believed to overcome several limitations of gene therapeutic treatments based on ex vivo lentiviral trials in the past. It is (i) targeting differentiated HIV target cells (i.e. liver and differentiated lymphatic cells) reducing the risk of genotoxicity compared to stem cell-based trials, (ii) overcoming the limitation of a low number of genetically modifiable cells as in lentivirally based ex vivo transduction strategies (i.e. limited modifiable cell number due to culture conditions and lower vector titers) and (iii) using the safe AAV vector system, which has not been associated with major genotoxicity in men. (iv) Most importantly, the concept of secretable entry inhibitors does not require transduction of large amounts of cells due to the protective bystander effect. Thus, iSAVE might be a treatment principle for HIV infection that might be able to cure patients irrespective of their viral isolates or adherence.
Accordingly, the iSAVE concept could aim at two different sites in the patient for the production of antiviral transgenes, either the systemic production via suitable producer cells (e.g. hepatocytes) or the local production in the lymphatic system.
In a first approach, we are able to efficiently target hepatocytes using the natural AAV serotype 8 to express high plasma levels of secretable antiviral entry inhibitors in order to systemically suppress viral replication. In this setting we could show that iSAVE peptides are highly expressed in hepatocytes. However, plasma levels of iSAVE were insufficient when using a secretable peptide as sole antiviral transgene.
As a second treatment strategy, the iSAVE project aimed to deliver antiviral genes directly to the site of viral replication, the lymphatic system. Here, (i) a panel of naturally occurring AAV serotypes as well as (ii) AAV retargeting approaches were employed to design a highly efficient and selective AAV vector variant for gene delivery into the lymphatic system after intravenous vector administration.
In detail, (i) screening of the natural occurring serotypes revealed that the AAV serotype 1 (AAV-1) was best in targeting splenic tissue in two humanized mouse models, however at a very low level. After systemic AAV-1 vector administration neither transduction of human lymphocytes did occur nor was iSAVE expressed in the lymphatic system in a humanized mouse model.
(ii) In a second approach, we modified the well-characterized AAV-2 serotype in a tropism-defining region of its capsid gene by insertion of human peripheral blood lymphocytes (hPBL)-tropic peptide ligands. These in turn were selected by M13 in vivo phage display and by in vivo AAV peptide display. Selected variants were cloned and tested for hPBL transduction in vitro. Although the selected variants did not show increased expression efficacies compared to AAV-2 WT, it still might be possible that the selected variant are more specific for hPBLs as these conditions have not been tested.
As these selection processes required a humanized mouse model that comprises a functional lymphatic system, we established the previously described Trimera mouse model in our lab (2). We found that this mouse model could be further improved to allow engraftment of a lower number of gene-modified (gm) human T cells as in the classical Trimera model. These modified Trimera mice (mT3 mice) were conditioned by inclusion of cyclophosphamide (CTX) to the irradiation-conditioning scheme of the classical Trimera model.
Comparison of mT3 mice with established NSG and DKO mice in an adoptive gm T cell transplantation setting revealed that NSG mice were the most robust model providing high reproducibility in human T cell engraftment. MT3 mice allowed a substantial, yet more variable engraftment of gm T cells. Besides comparing engraftment kinetics, the graft quality (i.e. clonality and cytokine milieu) was analyzed. Again, NSG mice showed the most balanced homeostatic repopulation three weeks after transplantation, while mT3 mice were prone to Th1-type, oligloclonal repopulation, indicating an early onset of xenograft-versus-host disease. Finally, the lymphatic infiltration was analyzed. As expected, mT3 mice provided the most intact lymphatic structures, although the normal lymphatic morphology was not restored.
In conclusion, it was demonstrated in this work that AAV-mediated iSAVE gene therapy faces specific limitations depending on the respective targeting approach
In the systemic approach, iSAVE peptides have to be further optimized in terms of transgene design itself, as high-level accumulation in murine plasma was not feasible for the short iSAVE precursor. In the local, lymphatic targeting approach, AAV-mediated expression faces its limits in targeting specificity but foremost expression efficacy. Thus, the AAV vector itself needs further optimization for sufficient local iSAVE expression levels. Independently from the AAV-related approaches, a novel humanized mouse model was established in this work. Despite drawbacks regarding repopulation variability and set-up complexity, the novel mT3 mouse model comprised improved secondary lymphatic structures for adoptive T cell transfer, which might be an interesting platform for studies in lymphoma or leukemia therapy.
Characterization of mouse NOA1 : subcellular localizaion, G-Quadruplex binding and proteolysis
(2013)
Mitochondria contain their own protein synthesis machinery with mitoribosomes that are similar to prokaryotic ribosomes. The thirteen proteins encoded in the mitochondrial genome are members of the respiratory chain complexes that generate a proton gradient, which is the electromotoric force for ATP synthesis.
NOA1 (Nitric Oxide Associated Protein-1) is a nuclear encoded GTPase that positively influences mitochondrial respiration and ATP production. Although a role in mitoribosome assembly was assigned to NOA1 the underlying molecular mechanism is poorly understood. This work shows that the multi-domain protein NOA1 serves multiple purposes for the function of mitochondria. NOA1 is a dual localized protein that makes a detour through the nucleus before mitochondrial import. The nuclear shuttling is mediated by a nuclear localization signal and the now identified nuclear export signal. SELEX (Systemic Evolution of Ligands by Exponential Enrichment) analysis revealed a G-quadruplex binding motif that characterizes NOA1 as ribonucleoprotein (RNP). G-quadruplex binding was coupled to the GTPase activity and increased the GTP hydrolysis rate. The sequence of localization events and the identification of NOA1 being a RNP lead to the discussion of an alternative import pathway for RNPs into mitochondria. The short-lived NOA1 contains ClpX recognition motifs and is specifically degraded by the mitochondrial matrix protease ClpXP. NOA1 is the first reported substrate of ClpXP in higher eukaryotes and augments the contribution of the ClpXP protease for mitochondrial metabolism. To assess the direct action of NOA1 on the mitoribosome co-sedimentation assays were performed. They showed that the interaction of NOA1 and the mitoribosome is dependent on the GTPase function and the nascent peptide chain. In vitro, NOA1 facilitated the membrane insertion of newly translated and isotope labeled mitochondrial translation products into inverted mitochondrial inner membrane vesicles. In conclusion, NOA1 is a G-quadruplex-RNP that acts as mitochondrial membrane insertion factor for mtDNA-encoded proteins.
This thesis provides a comprehensive model of the molecular function of NOA1 and is the basis for future research. The identification of NOA1 as ClpXP substrate is a major contribution to the field of mitochondrial research.
The YaeJ protein is a codon-independent release factor with peptidyl-tRNA hydrolysis (PTH) activity, and functions as a stalled-ribosome rescue factor in Escherichia coli. To identify residues required for YaeJ function, we performed mutational analysis for in vitro PTH activity towards rescue of ribosomes stalled on a non-stop mRNA, and for ribosome-binding efficiency. We focused on residues conserved among bacterial YaeJ proteins. Additionally, we determined the solution structure of the GGQ domain of YaeJ from E. coli using nuclear magnetic resonance spectroscopy. YaeJ and a human homolog, ICT1, had similar levels of PTH activity, despite various differences in sequence and structure. While no YaeJ-specific residues important for PTH activity occur in the structured GGQ domain, Arg118, Leu119, Lys122, Lys129 and Arg132 in the following C-terminal extension were required for PTH activity. All of these residues are completely conserved among bacteria. The equivalent residues were also found in the C-terminal extension of ICT1, allowing an appropriate sequence alignment between YaeJ and ICT1 proteins from various species. Single amino acid substitutions for each of these residues significantly decreased ribosome-binding efficiency. These biochemical findings provide clues to understanding how YaeJ enters the A-site of stalled ribosomes.
Im Mittelpunkt dieser Arbeit stand die Untersuchung der Reaktivität von Chlorsilanen gegenüber Elektronenpaardonoren. Als Basis hierfür diente die Alkylamin-katalysierte (NMe3, NMe2Et, NEt3) quantitative Disproportionierung von Si2Cl6 bzw. Si3Cl8 zum Neopentasilan 3 und SiCl4 (T ≤ RT, Schema 40). Obwohl diese Reaktion bereits seit über 60 Jahren bekannt ist, sind für ihren Mechanismus nur Vermutungen aufgestellt worden. In Kooperation mit der Gruppe um M. Holthausen ist es hier gelungen, das SiCl2-Amin-Addukt 57 als entscheidende Zwischenstufe zu identifizieren (1H29Si-HMBC-NMR-Experiment sowie DFT-Rechnungen). Si(SiCl3)4, die thermodynamische Senke des Systems, entsteht durch anschließende Insertion des Dichlorsilylens in Si−Cl-Bindungen – bevorzugt am höchst substituierten Si-Zentrum (es bilden sich keine linearen bzw. weniger verzweigten Oligosilane). Zudem lässt sich das koordinierte Amin vom SiCl2-Addukt wieder abspalten, was die Si(SiCl3)4-Synthese überhaupt erst ermöglicht. Dieses Verhalten unterscheidet sich grundlegend vom jenen literaturbekannter stabilisierter Chlorsilylene: hier bindet der Donor so stark an das Si-Atom, dass er den ambiphilen Charakter des Silylens zugunsten der Lewis-basischen Funktion einschränkt. Daher kann man mit diesen Addukten auch keine Oligosilane aufbauen, die mittlerweile auch das Interesse der chemischen Industrie erweckt haben...
C-Typ Lektin-ähnliche Rezeptoren (CTLRs) auf Lymphozyten des Immunsystems modulieren deren Effektorfunktionen wie Zytotoxizität oder Zytokinsekretion. Die Gene dieser Immunrezeptoren befinden sich in einer definierten genomischen Region, dem Natürlichen Killer Genkomplex (NKC), welcher im Menschen auf Chromosom 12 und in der Maus auf Chromosom 6 lokalisiert ist. Namensgebend für diesen Gencluster ist die erste Beschreibung von CTLRs auf Natürlichen Killerzellen (NK-Zellen), den Effektorlymphozyten des angeborenen Immunsystems. Einige NKC-kodierte CTLR, insbesondere Vertreter der C-Typ Lektin Familie 2 (CLEC2)-Rezeptorfamilie, werden jedoch auch in nicht-lymphozytären Zellen (z.B. humanes KACL in Keratinozyten, Maus Clr-f in Darmepithelzellen) vorgefunden und in Zusammenhang mit einer gewebsspezifischen Immunüberwachung gebracht. Bemerkenswerterweise sind die Lymphozytenassoziierten Rezeptoren dieser CLEC2-Proteine ebenso CTLRs, welche zudem eng benachbart zu den CLEC2-Proteinen im NKC kodiert sind, sodass es sich um genetisch gekoppelte Rezeptor-Liganden-Paare mit immunologischer Funktion handelt.
Zu Beginn der vorliegenden Arbeit richtete sich das Interesse auf ein bislang uncharakterisiertes Mitglied der CLEC2-Proteinfamilie (CLEC2L), das jedoch außerhalb des NKC und in unmittelbarer Nachbarschaft zu einem weiteren und ebenso uncharakterisierten CTLR (KLRG2) kodiert ist. Im Unterschied zu anderen Mitgliedern der CLEC2-Familie ist CLEC2L (wie auch KLRG2) in Säugetieren hochkonserviert. Im Rahmen dieser Arbeit wurde der Frage nachgegangen, ob CLEC2L wie andere Mitglieder der CLEC2-Proteinfamilie eine gewebsspezifische Expression aufweist, mit einem genetisch gekoppelten CTLR, d. h. mit KLRG2, interagiert und funktionell in Verbindung mit dem Immunsystem gebracht werden kann. Ziel dieser Arbeit war es somit, eine detaillierte Expressions- und Funktionsstudie zu CLEC2L durchzuführen.
Mittels quantitativer Echtzeit-PCR und in situ Hybridisierung konnte CLEC2L-RNA im humanen und Maus-Gehirn nachgewiesen werden. Da die Mengen dort das Expressionsniveau in anderen Organen bei Weitem überstiegen, wurde das CLEC2L-kodierte Protein als BACL (engl. Brain-Associated C-type Lectin) neu benannt. Ektop exprimiertes BACL bildet ähnlich wie viele andere CLEC2-Mitglieder ein disulfid-verknüpftes Homodimer auf der Zellmembran von Säugetierzellen. Um die endogene Proteinexpression dieses gehirnassoziierten „Waisen"-Rezeptors zu charakterisieren, wurde die BACL-Ektodomäne rekombinant produziert und als Immunogen zur Herstellung BACLspezifischer Antikörper eingesetzt. Mit diesen Antikörpern und einer Kombination immunologischer Techniken wie Immunhistochemie, Immunfluoreszenz und Immunpräzipitation konnte die Präsenz von BACL auf humanen und Maus-Neuronen des Gehirns mit einer besonders ausgeprägten Expression in Purkinje-Zellen zum ersten Mal gezeigt werden. Neben dem Gehirn wurden andere Bereiche des Nervensystems, darunter Spinalganglien und Retina, auf die Expression des BACL-Proteins untersucht. Hierbei konnte mittels Immunfluoreszenz und hochauflösender konfokaler Mikroskopie gezeigt werden, dass BACL mit Neuronenmembranen assoziiert ist. Die durchflusszytometrische Analyse von in vitro kultivierten Neurosphären untermauerte die Expression von endogenem BACL als membranständiges Oberflächenprotein.
Diverse Ansätze zur Identifizierung von Interaktionspartnern von BACL erbrachten letztlich keine eindeutigen Ergebnisse. KLRG2 wurde ursprünglich aufgrund seiner benachbarten genomischen Lokalisation als möglicher Rezeptor von BACL favorisiert, jedoch konnten weder Reporterassays noch durchflusszytometriebasierte Bindungsanalysen eine Interaktion dieser beiden Proteine aufzeigen. Auch die aus den massenspektrometrischen Analysen von humanen und Maus BACL-Immunpräzipitaten erhaltenen Kandidatenproteine konnten letztendlich nicht als Interaktionspartner von BACL eindeutig verifiziert werden.
Eine mögliche immunologische Bedeutung von BACL in vivo wurde im Rahmen von Tumorimplantationsexperimenten mit BACL-exprimierenden Tumorzellen untersucht. Hierbei wurde das Tumorwachstum von BACL- mit Kontroll-Transfektanten in C57BL/6 Mäusen verglichen. Der beobachtete Effekt des verlangsamten Tumorwachstums nach BACL-Überexpression war jedoch nicht auf BACL-Erkennung durch Lymphozyten zurückzuführen, wie anhand von immundefizienten Rag1-k.o. und NOD-SCID-gammak.o. Mäusen gezeigt werden konnte.
Insgesamt liefert diese Arbeit die Erstbeschreibung des bislang uncharakterisierten CTLRs BACL. Das Protein teilt strukturelle Merkmale mit Mitgliedern der CLEC2-Familie, unterscheidet sich jedoch deutlich durch (i) seine hohe Konservierung in Säugetieren, (ii) seine Kodierung außerhalb des NKC und (iii) seine pan-neuronale Expression. Die Erkenntnis, dass BACL in Maus- und in humanen Neuronen exprimiert wird, wirft die Frage nach seiner funktionellen Relevanz auf. Als Membranprotein könnte es eine wichtige Rolle in der neuronalen Kommunikation und bei zellulären Kontakten spielen. Die Frage nach der Funktion von BACL wird in zukünftigen Forschungsarbeiten zu klären sein.
Structural determinants for substrate specificity of the promiscuous multidrug efflux pump AcrB
(2013)
Opportunistic Gram-negative pathogens such as Escherichia coli, Klebsiella pneumoniae, Acinetobacter Baumanii and Pseudomonas aeruginosa are becoming more and more multiresistant against many commonly available antibiotics [39, 40]. An important resistance mechanism of Gram-negative bacteria is the efflux of noxious compounds by tripartite systems [39, 41-44]. The best studied and most clinically relevant tripartite system is the AcrA-AcrB-TolC system of Escherichia coli, where substrate recognition and energy transduction takes place in the inner membrane protein AcrB. AcrB has a remarkably huge substrate spectrum and can recognize structurally diverse molecules, such as hexan in contrast to erythromycin, as its substrates [45]. Therefore, overproduction of the tripartite system can render a Gram-negative pathogen resistant against multiple antibiotics at once. The mechanisms of how AcrB is able to recognize such an enormous spectrum of molecules as substrates, without compromising its specificity (e.g. by neglecting essential compounds like lipids or gluclose as its susbtates), remained puzzling. Structural insight into substrate specificity was so far limited to two co-crystal structures of AcrB, where minocycline and doxorubicin, respectively, were identified bound to an internal binding pocket of AcrB. This binding pocket is particularly deeply buried into internal parts of the T monomer of AcrB and was, therefore, denoted deep binding pocket (DBP). Analysis of several AcrB co-crystal structures with substrate molecules bound to the DBP [4, 23, 25] indicated that the substrate promiscuity involved multisite binding modes within the DBP. Multisite binding modes, where different substrate molecules can bind to slightly different positions and orientations to the same binding pocket, is a common feature of multidrug recognizing proteins such as QacR or BmrR [27-29]. Nevertheless, AcrB's substrate spectrum is much broader than substrate spectra of most other multidrug recognizing proteins. Therefore, it is likely that additional mechanisms are involved in mediating the observed high substrate promiscuity of AcrB. In our recently published high-resolution AcrB/doxorubicin co-crystal structure (pdb entry: 4DX7 [23]) we were able to identify two additional substrate binding pockets in the L monomer of AcrB: i) the access pocket (AP), with an opening towards the periplasm, and ii) a putative binding site in a groove between transmembrane helices 8 and 9 (TM8/TM9 groove), accessible from the lipid layer of the inner membrane. Both binding pockets are likely to be access sites for substrates towards AcrB. Furthermore, each of the binding pockets are possibly specialized to recognize a specific subset of the entire substrate spectrum of AcrB, i.e. highly hydrophobic substrates (e.g. n-dodecyl-ß-d-maltoside or sodium dodecylsulfate) might access AcrB towards the TM8/TM9 groove and water soluble substrates (e.g. berberine) might access AcrB towards the AP. Since substrates will accumulate in the membrane or the periplasm according to their hydrophilic or hydrophobic nature, substrates will be "pre-selected" by the medium, rather than by the protein itself, and guided to their appropriate access site. This process is proposed to be called "medium- mediated pre-selection". The AcrB/doxorubicin co-crystal structure (pdb entry: 4DX7 [23]) furthermore revealed that the AP and DBP are in next neighborhood to each other and are separated by a switch loop. This switch loop adopts distinct conformations in the L, T and O monomers. Specific switch loop conformations are strongly involved in coordinating the selective occupation of both binding pockets, the AP and the DBP. The conformation of the switch loop in the L monomer (L-switch loop) opens the AP and closes the DBP, whereas the conformation of the switch loop in the T monomer (T-switch Loop) opens the DBP and closes the AP. An analysis of all asymmetric AcrB structures indicated that the L-switch loop is able to adopt multiple distinct conformations, whereas the conformation of T-switch loop remained largely congruent in all crystal structures. Moreover, each distinct switch loop conformation, observed in co-crystal structures of AcrB with occupied AP [4, 23], was perfectly adapted to the bound substrate molecule. Therefore, the putatively flexible switch loop is likely to act as an adaptive module and mediates a high binding pocket plasticity without altering the global protein structure. This binding mode is called adaptor-mediated binding mechanism, where an flexible adaptive module (like the switch loop) is able to adapt the surface shape of an binding pocket to different substrate molecules. Furthermore, structural and biochemical analyses of an AcrB G616N variant, revealed the involvement of specific switch loop conformations in the substrate specificity of AcrB. A substitution of G616, located on the switch loop, to N616 was able to alter the conformation of the switch loop exclusively in the L monomers of AcrB, whereas the switch loop conformations in T and O monomers remained congruent to the conformations observed in crystal structures of wildtype AcrB. Moreover, cells producing the AcrB G616N and MexB, both bearing the G616N amino acid substitution, exhibited a reduced resistance against certain substrates, whereas the resistance against most other substrates remained on the level of wildtype AcrB. Correlations of the phenotypes with minimal projection areas, a novel 2-spatiodimensional parameter which approximates the size of a substrate molecule, revealed that AcrB variants with a G616N substitution have a reduced efflux activity for exclusively large substrate molecules. The rejection of large substrates is most likely connected with altered L-switch loop conformations....
1-(Bromomercurio)ferrocene
(2013)
The asymmetric unit of the title compound, [Fe(C5H5)(C5H4BrHg)], contains two independent molecules, A and B, in which the Hg-C bond lengths are 2.045 (6) and 2.046 (6) Å, the Hg-Br bond lengths are 2.4511 (9) and 2.4562 (7) Å, and the C-Hg-Br angles are 176.42 (17) and 177.32 (17)°. The two cyclopentadienyl rings of mol-ecule A are eclipsed, while those of mol-ecule B are almost staggered. The HgBr groups are connected by intermolecular Hg⋯Br contacts of 3.3142 (9)-3.4895 (11) Å, forming layers parallel to (001). These layers contain both four-membered (HgBr)2 and eight-membered (HgBr)4 rings. Ferrocene-ferrocene C-H⋯π contacts connect the molecular layers along the c-axis direction.
Metallorganische Netzwerke (engl. metal-organic frameworks, MOFs) sind eine neuartige Klasse mikro/mesoporöser Materialien, für die eine Vielzahl von möglichen Anwendungen demonstriert werden konnte. Das Ziel dieser Arbeit besteht in der Synthese von MOF Mikro/Nanopartikeln sowie der Herstellung von sogenannten Oberflächen-deponierten MOFs (engl. surface-attached metal-organic frameworks, SURMOFs). MOF Partikel mit kontrollierbarer Morphologie und Größe wurden unter milden Bedingungen synthetisiert. Um MOFs als Sensoren, intelligente Membrane, oder in nanotechnologischen Bauelementen verwenden zu können, ist die Integration auf der jeweiligen Oberfläche wichtig. Daher beschäftigt sich der Großteil dieser Arbeit mit der kontrollierten Abscheidung von SURMOFs auf verschiedenartigen Trägermaterialien. Etliche interessante Eigenschaften (z.B. die Fluoreszenz in Abhängigkeit von der Gegenwart von Gastmolekülen und die dynamische Gasadsorptionskapazität) der SURMOFs wurden untersucht.